Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Inflammation01:38

Inflammation

Overview
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis.

The New England journal of medicine·2025
Same author

Effect of Vericiguat on Total Heart Failure Events in Compensated Outpatients With HFrEF: Insights From VICTOR.

Journal of the American College of Cardiology·2025
Same author

Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials.

Lancet (London, England)·2025
Same author

Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial.

Lancet (London, England)·2025
Same author

Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial.

European heart journal·2025
Same author

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death.

The New England journal of medicine·2025

Related Experiment Video

Updated: May 8, 2026

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

Inflammation and atherosclerosis: disease modulating therapies.

Mahesh J Patel1, Michael A Blazing

  • 1Division of Cardiology, Duke University Medical Center, Durham, NC, USA, mahesh.patel@duke.edu.

Current Treatment Options in Cardiovascular Medicine
|August 28, 2013
PubMed
Summary

The immune system significantly impacts cardiovascular disease. While anti-inflammatory drugs show promise, more research is needed to confirm immune modulation as an effective treatment for atherosclerotic vascular disease.

Related Experiment Videos

Last Updated: May 8, 2026

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

Area of Science:

  • Cardiovascular immunology
  • Atherosclerosis research
  • Inflammation and vascular disease

Background:

  • The immune system plays a critical role in the development and progression of atherosclerotic vascular disease.
  • Elevated blood inflammation markers are independently associated with future cardiovascular events in humans.
  • Current anti-inflammatory treatments offer indirect support for immune modulation's potential benefits.

Purpose of the Study:

  • To review the current understanding of the immune system's role in atherosclerosis.
  • To discuss the limitations of existing evidence for anti-inflammatory strategies in cardiovascular disease.
  • To highlight the potential of upcoming clinical trials investigating targeted immune modulation for cardiovascular risk reduction.

Main Methods:

  • Review of mechanistic studies on atheroma.
  • Analysis of human studies linking inflammation markers to cardiovascular events.
  • Evaluation of evidence from statin and anti-inflammatory drug trials.
  • Discussion of ongoing and future clinical trials in immune modulation for cardiovascular disease.

Main Results:

  • Strong evidence supports the immune system's involvement in atherosclerotic vascular disease pathophysiology.
  • A clear association exists between elevated inflammation markers and increased cardiovascular event risk.
  • Indirect evidence suggests that modifying immune responses may improve cardiovascular outcomes, but direct proof is lacking.

Conclusions:

  • Targeted immune modulation represents a promising future treatment strategy for atherosclerotic vascular disease.
  • Further clinical trials are essential to establish the efficacy of immune modulation in improving cardiovascular outcomes.
  • Understanding atherosclerosis through immune system research will guide novel therapeutic approaches.